A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
Diseases of the Lung | Diseases of the Respiratory Systems
What is the purpose of this trial?
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.
- Ages18 years - 49 years
- GenderFemale only
- Trial withPfizer Inc., U.S. Pharmaceuticals Group
- Start Date04/02/2021
- End Date11/12/2023
- Last Updated06/02/2022
- Study HIC#2000029265